Laidlaw Downgrades Intercept Pharmaceuticals (ICPT) to Sell
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Laidlaw downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Buy to Sell with a price target of $105, implying downside of 40%. Analyst Jim Molloy lowered expectations for OCA for NASH.
"The company indicated that FY17 operating expenses are likely to be higher than the $360M $400M spend for FY16, and that the uptake of Ocaliva for PBC in the US and the EU should be expected to proceed at a rather moderated pace. The company has ~$850M in cash (pro-forma) following the July convertible debt offering (which netted ~$409M), which at ICPT’s current prolific spending means they will be down to a year of cash in 2017 (again). While the company has been adept at raising prodigious amounts of capital to date, a key architect of that fund raising ability – former CFO Duncan – has stepped aside for new CFO Kapadia," said Molloy.
The analyst continued, "ICPT’s key asset, OCA for NASH, remains the main reason to own the stock but the pivotal REGENERATE Phase 3 trial data is now a 2019 event (from 2H18 previously), and the important CONTROL lipid study is now a 2H17 event (from 4Q16 previously). ICPT is currently rolling out an expensive worldwide infrastructure to launch a single orphan drug – Ocaliva – which can mean years of slogging to profitability unless additional products can be found to add to the reps’ bags to help more fully utilize the sales force. Our new price target incorporates what we believe are more conservative rollout expectations for Ocaliva for PBC and OCA for NASH, and also incorporates the now extended launch timelines."
Molloy, added, "Most of our lowered PT comes from somewhat more conservative launch expectations for OCA for NASH, and also from our expectations for the launch to be pushed out at least another year to 2H20 (from 2019 previously)."
Shares of Intercept Pharmaceuticals closed at $163.21 yesterday.
(Updated - August 5, 2016 8:48 AM EDT) (Update corrects prior rating.)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pivotal Research Downgrades Kroger (KR) to Hold
- Tesla's (TSLA) Price Target Cut to Street Low of $155 at Cowen
- UPDATE: Oppenheimer Starts Shopify (SHOP) at Perform
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades, Hot Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!